Wedmont Private Capital Has $1.51 Million Stock Position in Organon & Co. $OGN

Key Points

• Wedmont Private Capital increased its holdings in Organon & Co. by 233.9% during the second quarter, now owning a total of 152,118 shares valued at approximately $1.5 million.
• Organon & Co. reported $1.00 earnings per share for the last quarter, exceeding analyst estimates, despite a 0.8% decline in year-over-year quarterly revenue.
• The company announced a quarterly dividend of $0.02 per share, reflecting an annualized payout of $0.08 and a yield of 0.7%.

Wedmont Private Capital raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 233.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 152,118 shares of the company's stock after purchasing an additional 106,561 shares during the period. Wedmont Private Capital owned about 0.06% of Organon & Co. worth $1,507,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Organon & Co. by 870.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company's stock worth $15,051,000 after acquiring an additional 906,675 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Organon & Co. by 8.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock worth $159,553,000 after acquiring an additional 820,378 shares during the period. Goldman Sachs Group Inc. boosted its position in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock worth $21,370,000 after acquiring an additional 801,307 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Organon & Co. during the 4th quarter worth $11,892,000. Finally, Siemens Fonds Invest GmbH acquired a new stake in shares of Organon & Co. in the fourth quarter valued at $8,998,000. 77.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Organon & Co. has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Organon & Co. Trading Down 3.6%

Shares of NYSE OGN traded down $0.39 during mid-day trading on Friday, hitting $10.46. 9,658,470 shares of the company traded hands, compared to its average volume of 3,489,394. Organon & Co. has a 1 year low of $8.01 and a 1 year high of $20.09. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 3.89, a PEG ratio of 0.99 and a beta of 0.60. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The business has a 50 day moving average of $9.69 and a two-hundred day moving average of $10.73.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. During the same period in the prior year, the business posted $1.12 earnings per share. Organon & Co.'s revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Organon & Co.'s payout ratio is presently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.